BMJ 1994;308:995-996 (16 April)

Editorials

Vascular disease: the next target for local molecular therapeutics

The resistance of atherosclerosis to conventional treatments reflects the complex pathogenesis of mature atheroma. The disease is diffuse, but the symptomatic lesions are often localised, and bypassing large stenosing plaques with vein grafts has been the mainstay of palliation. For the past 15 years, however, percutaneous transluminal coronary angioplasty has been used increasingly. In 1990 over 300 000 of these procedures were carried out in the United States1 and about 8500 in Britain.2 This number is still rising, but enthusiasm has been tempered by symptomatic restenosis in about one third of cases.3 Late recoil of the stretched vessel may contribute, but a rapid proliferation of vascular smooth muscle cells within the intima is the striking feature of restenosis, and this fibrocellular intimal hyperplasia has resisted all pharmacological interventions examined so far.3 Attention has turned to less conventional treatments, particularly genetic manipulation of the arterial wall to alter its response to . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Li, J.-M., Brooks, G. (1999). Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?. Eur Heart J 20: 406-420  
  • Gershlick, A. (1998). Endovascular manipulation to restrict restenosis. Vasc Med 3: 177-188 [Abstract]  
Access all current jobs at BMJ Group
Whats new online at Student BMJ
Listen to the latest BMJ Interview